TransCode Therapeutics announced that its board of directors has initiated a formal strategic process to evaluate opportunities designed to maximize the value of the Company and its oncology portfolio, including its lead product candidate, TTX-MC138. The company engaged Tungsten Advisors as exclusive financial advisor to assess a broad range of potential transactions involving the company, its lead therapeutic candidate TTX-MC138, and other oncology programs. Potential opportunities may include licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions, business combinations, or other strategic transactions. There is no assurance that the process will result in any transaction. TransCode Therapeutics is a clinical-stage biopharmaceutical company developing RNA-based therapeutics and immuno-oncology treatments for high-risk and advanced cancers.
